FDA Requires New Warnings on Drugs in the JAK Inhibitors Class
September 1, 2021ICU Medical Recalls Aminosyn II Because of Particulate Matter
September 7, 2021September 1, 2021 – Invega HafyeraTM (paliperidone palmitate) extended-release injectable suspension is now the first FDA-approved twice-yearly treatment for schizophrenia.
Made by Janssen, the drug is indicated for use in adults who have been adequately treated with:
- A once-monthly paliperidone palmitate extended-release injectable suspension, such as Janssen's Invega Sustenna®, for at least four months, or
- An every-three-month paliperidone palmitate extended-release injectable suspension, such as Janssen's Invega Trinza®, for at least one three-month cycle.
- Recommended dosing is determined based on the patient's prior treatment history. Invega Hafyera should be given via gluteal intramuscular injection by a healthcare professional once every six months.
- Invega Hafyera has launched at a wholesale acquisition cost (WAC) of $11,760.28 per syringe.